Celyad Oncology SA
XBRU:CYAD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2295
1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Celyad Oncology SA
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
| Market Cap | P/OCF | ||||
|---|---|---|---|---|---|
| BE |
|
Celyad Oncology SA
XBRU:CYAD
|
14.7m EUR | -1.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -237 521.5 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
320.1B USD | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
150.5B USD | 20.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.4B USD | -142.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
113.8B USD | 11.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -473.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.4B AUD | 31.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.9B USD | 19.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -76.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
34.5B EUR | -139.5 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
You don't have any saved screeners yet
